CompletedNot Applicable

BFR Walking for Insulin and Aerobic Improvement in Type 2 Diabetes

Palestinian Territories60 participantsStarted 2022-03-06

Plain-language summary

This clinical trial examines the impact of Blood-Flow Restriction Walk Training (BFRw) on insulin sensitivity and aerobic capacity in individuals with Type 2 Diabetes (T2D). The primary objectives of the study are to determine: If Blood-Flow Restriction Walk Training (BFRw) can improve insulin sensitivity in individuals with Type 2 Diabetes (T2D). Whether Blood-Flow Restriction Walk Training (BFRw) enhances aerobic capacity in individuals with Type 2 Diabetes (T2D). Participants in the study are divided into two groups. One group undergoes Blood-Flow Restriction Walk Training (BFRw), and the other serves as a control. Both groups attend three treadmill walking sessions weekly for eight weeks. The BFRw group has a restriction cuff placed around both thighs during their sessions, while the control group participates in the walking sessions without any blood flow restriction. Hemoglobin A1c (HbA1c) levels and maximal oxygen consumption (VO2 max) are monitored as indicators of insulin sensitivity and aerobic capacity, respectively.

Who can participate

Age range40 Years – 65 Years

SexMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Male individuals of Palestinian descent * Aged between 40 to 65 years * Diagnosed with Type 2 Diabetes for a duration of 2 to 10 years, with ongoing medical supervision * Capable of understanding and following the study's instructions, programs, and protocols Exclusion Criteria: * Females, due to hormonal and metabolic differences. * Individuals outside the 40-65 age range to minimize age-related variations in Diabetes Mellitus. * Patients with conditions or comorbidities that impair walking or elevate the risk associated with Blood-Flow Restriction Training (BFRT). * An Ankle Brachial Pressure Index (ABI) greater than 0.9, as values outside the normal range (0.9 to 1.4) may indicate Peripheral Arterial Disease (PAD) or Cardiovascular Disease (CVD), affecting eligibility for participation.

What they're measuring

Improvement in Insulin Sensitivity

Timeframe: 8 weeks

Improvement in Aerobic Capacity

Timeframe: 8 weeks

Trial details

NCT IDNCT06290947

SponsorArab American University (Palestine)

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-12-20